2.2 Molecular Mechanisms of Antimicrobial Resistance

Molecular Mechanisms of Antimicrobial Resistance

Bacterial resistance to antimicrobial agents represents an evolving clinical challenge driven by complex genetic and biochemical mechanisms. Bacteria deploy four fundamental strategies: enzymatic drug inactivation, modification of drug binding targets, decreased membrane permeability, and active extrusion via multidrug efflux pumps. Mastery of these molecular pathways is essential for selecting effective antimicrobial regimens and anticipating clinical failure.

---

Enzymatic Inactivation: Beta-Lactamases

Beta-lactamases hydrolyze the amide bond within the four-membered beta-lactam ring, rendering the antibiotic microbiologically inactive. The Ambler molecular classification categorizes beta-lactamases into four distinct classes (A, B, C, D) based on primary amino acid sequence homology and catalytic mechanism.

                     ┌──────────────────────────────────────────────┐
                     │       Ambler Classification Scheme           │
                     └──────────────────────┬───────────────────────┘
                                            │
            ┌───────────────────────────────┴───────────────────────────────┐
            ▼                                                               ▼
┌───────────────────────────────┐                               ┌───────────────────────────────┐
│   Serine Beta-Lactamases      │                               │ Metallo-Beta-Lactamases (MBL) │
│  (Active-site Serine Hydrolase)│                               │    (Zinc Divalent Cations)    │
└───────────┬───────────────────┘                               └───────────────┬───────────────┘
            │                                                                   │
   ┌────────┼────────┐                                                          ▼
   ▼        ▼        ▼                                                       Class B
Class A  Class C  Class D                                             (NDM, VIM, IMP, SPM)
(TEM,    (AmpC)   (OXA-48,                                            - Hydrolyze carbapenems
 SHV,              OXA-23)                                            - Inactivated by EDTA
 CTX-M,                                                               - Resist CAZ-AVI, MER-VAB
 KPC)                                                                 - Sparingly active: Cefiderocol,
                                                                        Aztreonam + Avibactam

Ambler Class Overview

Inducible Chromosomal AmpC Cephalosporinases

Certain Gram-negative species harbor an inducible chromosomal ampC gene regulated by ampR (transcriptional regulator), ampG (permease), and ampD (cytosolic amidase). Historically grouped under mnemonics such as SPACE (Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter) or HECK (Hafnia, Enterobacter, Citrobacter, Klebsiella aerogenes), contemporary clinical data demonstrate that the risk of clinically significant, stable derepression is highest in three core organisms:

1. Enterobacter cloacae complex
2. Klebsiella aerogenes (formerly Enterobacter aerogenes)
3. Citrobacter freundii

---

Other Enzymatic Inactivation Mechanisms

Aminoglycoside-Modifying Enzymes (AMEs)

Aminoglycosides exert bactericidal activity by binding the 30S ribosomal subunit. Resistance occurs through plasmid-borne enzymes that chemically modify hydroxyl or amino functional groups on the aminoglycoside core, stericly blocking ribosomal binding:

• Acetyltransferases (AAC): Catalyze acetyl-CoA-dependent acetylation of amino groups (e.g., AAC(6')-Ib confers resistance to tobramycin, amikacin, and kanamycin).
• Phosphotransferases (APH): Catalyze ATP-dependent phosphorylation of hydroxyl groups (e.g., APH(3')-Ia confers resistance to neomycin and kanamycin).
• Nucleotidyltransferases (ANT): Catalyze ATP-dependent adenylylation of hydroxyl groups (e.g., ANT(2")-Ia confers resistance to gentamicin and tobramycin).

Plazomicin is a synthetic next-generation aminoglycoside engineered with a hydroxy-aminobutyric acid (HABA) substituent and an unsaturated hydroxyethyl side chain that blocks steric binding of nearly all clinically prevalent AMEs, maintaining potent activity against CRE and ESBL-producing isolates. However, plazomicin is inactivated by 16S ribosomal RNA methyltransferases (such as ArmA and RmtB), which confer pan-aminoglycoside resistance.

Macrolide Inactivation

Bacteria produce macrolide esterases (ereA, ereB) that hydrolyze the 14- or 15-membered lactone ring of erythromycin and azithromycin, or macrolide phosphotransferases (mphA) that phosphorylate the 2'-hydroxyl group of the desosamine sugar.

---

Target Site Alterations

Target site modification prevents antimicrobial binding through point mutations in target genes, post-transcriptional ribosomal methylation, or acquisition of alternative biosynthetic enzymes.

Target Site Alteration Mechanisms:
├── PBP Alteration (mecA/mecC -> PBP2a) ─────────► Staphylococcal Methicillin Resistance (MRSA)
├── Peptidoglycan Precursor (D-Ala-D-Ala -> D-Ala-D-Lac) ► Enterococcal Vancomycin Resistance (vanA/vanB)
├── 23S rRNA Methylation (ermA/B/C) ─────────────► Inducible MLSB Phenotype (Clindamycin Resistance)
├── Topoisomerase Mutations (gyrA / parC) ──────► Fluoroquinolone Resistance (Ciprofloxacin/Levofloxacin)
└── RNA Polymerase Beta Subunit (rpoB) ──────────► Rifampin Resistance

Staphylococcal Methicillin Resistance: mecA and mecC

Methicillin resistance in Staphylococcus aureus (MRSA) and coagulase-negative staphylococci is mediated by the mobile genetic element Staphylococcal Cassette Chromosome mec (SCCmec). This element carries mecA (or its divergent homolog mecC), which encodes penicillin-binding protein 2a (PBP2a). While native PBPs (PBP1, PBP2, PBP3) are acylated and inactivated by beta-lactams, PBP2a possesses an altered active-site geometry with an exceptionally low binding affinity for penicillins, cephalosporins, and carbapenems. PBP2a continues transpeptidating cell wall peptidoglycan despite therapeutic beta-lactam concentrations.

• Exceptions: Ceftaroline and ceftobiprole are advanced-generation cephalosporins designed to bind an allosteric pocket on PBP2a, triggering a conformational change that permits high-affinity active-site acylation and staphylocidal activity.

Enterococcal Vancomycin Resistance: van Gene Operons

Vancomycin binds with high affinity to the C-terminal D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan lipid II pentapeptide precursors via five hydrogen bonds, blocking transglycosylation and transpeptidation.

• vanA Operon: Acquired plasmid-mediated transposable element (Tn1546) triggered by vancomycin or teicoplanin. Encodes VanA (ligase synthesizing D-alanyl-D-lactate [D-Ala-D-Lac]), VanX (D,D-dipeptidase cleaving native D-Ala-D-Ala), and VanY (carboxypeptidase). The substitution of an ester linkage (lactate) for an amide linkage eliminates one critical hydrogen bond, reducing vancomycin binding affinity by ~1,000-fold. Results in high-level resistance to both vancomycin (MIC $\ge 64\text{ mg/L}$) and teicoplanin.
• vanB Operon: Synthesizes D-Ala-D-Lac, but transcription is induced exclusively by vancomycin, not teicoplanin. Isolates appear resistant to vancomycin but susceptible in vitro to teicoplanin (though teicoplanin resistance emerges readily during therapy).
• vanC Phenotype: Native, chromosomal, non-transferable low-level resistance found constitutively in Enterococcus gallinarum and Enterococcus casseliflavus. Involves alteration to D-alanyl-D-serine (D-Ala-D-Ser), producing moderate vancomycin MICs (typically 4–32 mg/L) without teicoplanin cross-resistance.

Inducible $MLS_B$ Resistance and the D-Test

Macrolides (erythromycin, azithromycin), lincosamides (clindamycin), and streptogramin B compounds share overlapping binding sites on the 23S rRNA component of the bacterial 50S ribosomal subunit ($MLS_B$ group).

• Mechanism: The erm (erythromycin ribosome methylase) gene family (ermA, ermB, ermC) encodes methyltransferases that add one or two methyl groups to adenine residue A2058 in the 23S rRNA. This sterically impedes binding of all $MLS_B$ agents.
• Phenotypes:
  • Constitutive $MLS_B$: Continuous enzyme expression; isolate tests resistant in vitro to both erythromycin and clindamycin.
  • Inducible $MLS_B$: Enzyme synthesis is repressed until an inducer is present. 14- and 15-membered macrolides (erythromycin) are strong inducers of the erm mRNA attenuator; clindamycin is a weak inducer. Consequently, in vitro disk diffusion or automated AST displays erythromycin resistance but apparent clindamycin susceptibility.
  • Efflux-mediated resistance ($msrA$ / $mefA$): Operates an active efflux pump specific for macrolides; clindamycin remains fully active and susceptible without risk of failure.

Fluoroquinolone and Rifampin Target Mutations

• Fluoroquinolones: Inhibit DNA gyrase (gyrA, gyrB) and topoisomerase IV (parC, parE), halting bacterial DNA replication. High-level resistance develops stepwise through non-synonymous point mutations in the Quinolone Resistance-Determining Regions (QRDR), typically Ser83Leu and Asp87Asn in gyrA combined with Ser80Ile in parC.
• Rifampin: Inhibits bacterial DNA-dependent RNA polymerase by binding the $\beta$-subunit (rpoB). A single point mutation within the conserved 81-base-pair rifampin resistance-determining region (RRDR) of rpoB (such as His526Tyr or Ser531Leu) confers complete, high-level clinical resistance. Rifampin must never be deployed as monotherapy for active bacterial infections.

---

Decreased Permeability and Efflux Systems

Porin Loss in Pseudomonas aeruginosa

Gram-negative outer membranes contain non-specific and substrate-specific protein channels called porins. In P. aeruginosa, entry of carbapenems into the periplasmic space depends upon the OprD outer membrane porin. Mutational disruption, transcriptional downregulation, or loss of oprD abolishes carbapenem penetration. Because imipenem depends strictly on OprD while meropenem relies partially on alternative channels, oprD silencing produces profound imipenem resistance while meropenem MICs may exhibit only moderate elevation.

Multidrug Resistance (MDR) Efflux Pumps

Efflux pumps span the inner membrane, periplasm, and outer membrane to actively export antimicrobials:

• Pseudomonas aeruginosa (Mex Systems): Resistance-Nodulation-Division (RND) tripartite family systems:
  • MexAB-OprM: Overexpression confers resistance to beta-lactams (piperacillin, ceftazidime, cefepime, meropenem), fluoroquinolones, and tetracyclines. Note that imipenem is not an efflux substrate for MexAB-OprM.
  • MexXY-OprM: Overexpression exports aminoglycosides, fluoroquinolones, and cefepime.
• Acinetobacter baumannii (AdeABC): RND pump conferring multidrug resistance across aminoglycosides, beta-lactams, fluoroquinolones, and tigecycline.

Colistin and Polymyxin Resistance

Polymyxins (colistin [polymyxin E] and polymyxin B) act by electrostatic binding to negatively charged phosphate groups on Lipid A of Gram-negative lipopolysaccharide (LPS), displacing stabilizing $Mg^{2+}$ and $Ca^{2+}$ ions to disrupt outer membrane integrity.

• Target Modification: Resistance occurs via the covalent addition of positively charged moieties—phosphoethanolamine (pEtN) or 4-amino-4-deoxy-L-arabinose (L-Ara4N)—to Lipid A, neutralizing its negative charge and abolishing polymyxin binding affinity.
• Chromosomal Mutations: Alterations in two-component sensor kinase/regulator systems (pmrA/pmrB, phoP/phoQ) or loss-of-function mutations in mgrB (a negative regulator of PhoP/PhoQ in K. pneumoniae) cause constitutive hyper-activation of the arnBCADTEF lipid modification operon.
• Plasmid-Mediated Resistance (mcr Genes): mcr-1 through mcr-10 encode phosphoethanolamine transferases on transmissible plasmids, facilitating horizontal interspecies dissemination of polymyxin resistance among Enterobacterales.